6-K - LakeShore Biopharma Co., Ltd | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

LakeShore Biopharma's Special Committee received a revised preliminary non-binding proposal dated March 24, 2026, from Oceanpine Skyline Inc. and Oceanpine Merger Sub Inc. to acquire all outstanding ordinary shares not owned by them or affiliates at US$0.06 per share, citing arbitral awards of RMB576.5 million as causing a Company Material Adverse Effect.

Key Takeaways

1Special Committee received Proposal Letter dated March 24, 2026

2Proposed purchase price: US$0.06 per Ordinary Share, 50% premium to March 20, 2026 closing price

3Triggered by Kaifeng Arbitration Commission awards on January 21-22, 2026 totaling RMB576.5 million against PRC subsidiaries

4Revises Merger Agreement dated November 4, 2025

5Non-binding; no assurance of definitive agreement or consummation

6Special Committee to evaluate with financial and legal advisors

Current Report Details

Event Type

Securities Issuance

Disclosure

Voluntary

Variant

6-K

Items Reported

6-K

Current Report on Form 6-K

Securities Issuance

Transaction Details

Acquisition / Disposition

Target: LakeShore Biopharma Co., Ltd
Consideration: US$0.06 per Ordinary Share
Structure: all cash transaction funded by rollover equity and cash contribution by Oceanpine Capital Inc. or affiliates

•Preliminary non-binding proposal
•Special Committee to evaluate with advisors
•Amendments to Merger Agreement and related documents needed
•No decisions made; no assurance of execution or consummation

Exhibits (2)

6-K

REPORT OF FOREIGN PRIVATE ISSUER

99.1

PRESS RELEASE - LAKESHORE BIOPHARMA ANNOUNCES RECEIPT OF A REVISED PRELIMINARY NON-BINDING PROPOSAL TO ACQUIRE THE COMPANY